Company Description
Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally.
Its robotic magnetic navigation (RMN) systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites.
The company provides Odyssey, a real-time information solution to manage, control, record, and share procedures across networks; and Stereotaxis Imaging Model S X-ray system, a single-plane, full-power x-ray system, including c-arm, powered table, motorized boom, and monitors for a robotic interventional operating room.
In addition, it offers disposables and other accessories, such as QuikCAS automated catheter advancement disposables for the remote advancement of electrophysiology catheters.
Further, the company provides Vdrive, a system that offers navigation and stability for the diagnostic and therapeutic devices designed to improve interventional procedures; and V-Loop, V-Sono, and V-CAS disposable components.
It markets its products through direct sales force, distributors, and sales agents. The company has a strategic collaboration with MAGiC catheter for cardiac ablation procedures.
Stereotaxis, Inc. was incorporated in 1990 and is based in Saint Louis, Missouri.
| Country | United States |
| Founded | 1990 |
| IPO Date | Aug 12, 2004 |
| Industry | Medical Instruments & Supplies |
| Sector | Healthcare |
| Employees | 122 |
| CEO | David Fischel |
Contact Details
Address: 710 North Tucker Boulevard, Suite 110 Saint Louis, Missouri 63101 United States | |
| Phone | 314 678 6100 |
| Website | stereotaxis.com |
Stock Details
| Ticker Symbol | STXS |
| Exchange | NYSEAMERICAN |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001289340 |
| CUSIP Number | 85916J409 |
| ISIN Number | US85916J4094 |
| Employer ID | 94-3120386 |
| SIC Code | 3845 |
Key Executives
| Name | Position |
|---|---|
| Dr. David Leo Fischel C.A.I.A., C.F.A., C.P.A., M.B.A. | Chief Executive Officer and Chairman |
| Keith Galloway | Vice President of Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 14, 2024 | 10-Q | Quarterly Report |
| Nov 12, 2024 | 8-K | Current Report |
| Sep 11, 2024 | EFFECT | Notice of Effectiveness |
| Sep 6, 2024 | S-3/A | [Amend] Registration statement under Securities Act of 1933 |
| Sep 6, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Aug 30, 2024 | UPLOAD | Filing |
| Aug 23, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Aug 23, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| Aug 15, 2024 | D | Notice of Exempt Offering of Securities |
| Aug 14, 2024 | 10-Q | Quarterly Report |